Large vessel vasculitis (LVV) is classified into giant cell arteritis (GCA) in the elderly and Takayasu arteritis (TAK) in the young. In both cases, corticosteroids are still the mainstay of treatment. In addition, conventional synthetic disease modifying antirheumatic drugs (csDMARDs) such as methotrexate and biological DMARDs such as tocilizumab and infliximab are used. However, there are still many cases in which remission cannot be achieved with these drugs, cases in which multiple relapses occur, and cases in which the dose of corticosteroids cannot be reduced.
Recently, several clinical trials using new therapeutic agents have been conducted, and the results seem promising so far.
This Research Topic will summarize the results of clinical trials of new drugs that may be available in the near future, such as anti-IL-12/IL-23 antibodies, anti-IL-17 antibodies, abatacept, granulocyte macrophage colony-stimulating factor (GM-CSF) receptor antibodies, and Janus kinase (JAK) inhibitors. This research topic will also summarize the basic research that supports their effectiveness.
Additionally, this research topic will provide new potential therapeutic targets for treating LVV as well as methods for finding new therapeutic targets. Different measures of treatment outcomes, such as relapses, glucocorticoid toxicity and patient reported outcomes will also be discussed. Through these processes, we would like to update on the latest treatments for LVV, including GCA and TAK.
This Research Topic will provide an overview of current and upcoming therapeutic options in GCA. These include for example, anti-IL-12/IL-23 antibodies, anti-IL-17 antibodies, abatacept, GM-CSF receptor antibodies, and JAK inhibitors. Also, options for patient stratification for different treatment options, based on clinical or immunological characteristics, will be considered. We hope to stimulate a scientific conversation and increase the knowledge about this topic.
We welcome the submission of Original Research and Review/Mini-Review articles that involve all aspects of this topic, focusing on, but not limited to:
• Pathomechanisms
• Biomarkers
• Current and upcoming Treatment
• Next therapeutic target
Large vessel vasculitis (LVV) is classified into giant cell arteritis (GCA) in the elderly and Takayasu arteritis (TAK) in the young. In both cases, corticosteroids are still the mainstay of treatment. In addition, conventional synthetic disease modifying antirheumatic drugs (csDMARDs) such as methotrexate and biological DMARDs such as tocilizumab and infliximab are used. However, there are still many cases in which remission cannot be achieved with these drugs, cases in which multiple relapses occur, and cases in which the dose of corticosteroids cannot be reduced.
Recently, several clinical trials using new therapeutic agents have been conducted, and the results seem promising so far.
This Research Topic will summarize the results of clinical trials of new drugs that may be available in the near future, such as anti-IL-12/IL-23 antibodies, anti-IL-17 antibodies, abatacept, granulocyte macrophage colony-stimulating factor (GM-CSF) receptor antibodies, and Janus kinase (JAK) inhibitors. This research topic will also summarize the basic research that supports their effectiveness.
Additionally, this research topic will provide new potential therapeutic targets for treating LVV as well as methods for finding new therapeutic targets. Different measures of treatment outcomes, such as relapses, glucocorticoid toxicity and patient reported outcomes will also be discussed. Through these processes, we would like to update on the latest treatments for LVV, including GCA and TAK.
This Research Topic will provide an overview of current and upcoming therapeutic options in GCA. These include for example, anti-IL-12/IL-23 antibodies, anti-IL-17 antibodies, abatacept, GM-CSF receptor antibodies, and JAK inhibitors. Also, options for patient stratification for different treatment options, based on clinical or immunological characteristics, will be considered. We hope to stimulate a scientific conversation and increase the knowledge about this topic.
We welcome the submission of Original Research and Review/Mini-Review articles that involve all aspects of this topic, focusing on, but not limited to:
• Pathomechanisms
• Biomarkers
• Current and upcoming Treatment
• Next therapeutic target